Zai Lab Limited (ZLAB)
ZLABNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$27.22
+1.74 (+6.84%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $3.02bn
- P/E
- –
- EPS, last 4 quarters
- $-1.79
- Dividend yield
- –
- Day range
- –
- 52-week range
- $15.96 to $27.50
- Average volume
- 957.1k
- Previous close
- $25.48
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $39.33, +44.5% from here
Earnings
Next report
Dec 2025
-4.5%
Mar 2026
+20.7%
Jun 2026
–
Sep 2026
–
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $127.60m | $99.61m | $106.31m | $108.21m |
| Gross profit | $65.27m | $61.28m | $58.15m | $56.90m |
| Operating income | -$69.41m | -$69.39m | -$76.49m | -$62.98m |
| Net income | -$50.41m | -$51.02m | -$50.83m | -$46.14m |
Last four quarters: revenue $441.73m, margin -44.9%, free cash flow -$163.34m
News
8 latest- Consensus Price Target for Zai Lab Limited - Depositary Receipt Increased by 12.10% to $31.30Fintel · 10 hours ago
- Zai Lab Q3 Earnings Call HighlightsMarketBeat · 3 days ago
- Zai Lab (ZLAB) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- Zai Lab Limited Reports Third Quarter 2026 Financial Results and $250.0 Million Private PlacementFintel · 4 days ago
- Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · 5 days ago
- Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer StudyMarketBeat · Oct 23, 2026
- Zai Lab Limited Announces $250 Million Private PlacementFintel · Oct 23, 2026
- Zai Lab (ZLAB) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 13, 2026
The company
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Asia
- Website
- zailaboratory.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.